Catalyst
Slingshot members are tracking this event:
Novartis (NVS) Presents Phase 3 MONALEESA-2 Data Evaluating LEE011 + Femara in Patients with Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 09, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Monaleesa-2, Lee011, Femara, Hormone-receptor Positive, Hr+, Her2-, Advanced Breast Cancer, Metastatic Breast Cancer, Ribociclib
